Sg3 Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $415,700 - $729,950	-5,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$110.08 - $142.92 $3.58 Million - $4.64 Million	-32,500 Reduced 86.67%	5,000 $593,000
Q4 2021 Feb 15, 2022	BUY	$99.73 - $148.48 $329,109 - $489,983	3,300 Added 9.65%	37,500 $5.17 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $1.22 Million - $1.85 Million	-18,800 Reduced 35.47%	34,200 $2.93 Million
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $1.54 Million - $3.93 Million	53,000 New	53,000 $3.88 Million
Q3 2019 Nov 13, 2019	SELL	$37.38 - $49.47 $437,346 - $578,799	-11,700 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$39.79 - $67.01 $465,543 - $784,017	11,700 New	11,700 $512,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.